Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renvela vs Etalpha in Stage 3B Renal Failure
NCT01231438Phase 2Completed
- Sponsor
- Stavanger University Hospital
- Start
- Oct 2010
- Primary completion
- Mar 2011
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sevelamer carbonate in kidney failure (ESRD) (2 arms), sponsored by Stavanger University Hospital. Primary endpoint: FGF23 serum level at 2 weeks. Started Oct 2010; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
kidney failure (ESRD)
Beyond the preview
Go deeper on NCT01231438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231438.